Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"

Core Viewpoint - Anixa Biosciences' breast cancer vaccine has the potential to revolutionize breast cancer prevention by targeting the disease at its earliest stages, as highlighted in a feature on Fox News' "America Reports" [1][3] Company Overview - Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program and vaccines for breast cancer and other malignancies [5] Vaccine Development - The breast cancer vaccine is designed to train the immune system to recognize and eliminate cancerous cells before they develop into invasive tumors, specifically targeting the lactation protein α-lactalbumin, which is expressed in malignant breast cancer cells [2] - The Phase I clinical trial, conducted in collaboration with Cleveland Clinic and funded by a U.S. Department of Defense grant, shows promising progress with over 70% of patients demonstrating protocol-defined immune responses [3] Future Plans - A Phase 2 study in the neoadjuvant setting is planned to begin in 2025, representing a critical milestone in the vaccine's continued development [3]